Biotech Values

[biomaven0]

NVS' recent failure to win approval for its gout drug

RDEA is my pick in the gout space. I think it could work as an add-on to pretty much any other therapy, but mostly should work well as a 2nd line therapy (on top of allopurinol). That's potentially a bigger market than the 3rd line drugs like Savient's Krystexxa).

Stock isn't real cheap though - unclear to me how much of their market cap is attributable to their gout drug and how much to their partnered MEK inhibitor.

Peter